Episode 36. ASH 2023 Lymphoma Recap with Dr. Toby Eyre
Blood Cancer Talks
Comparing FCR and M.R.D.-guided therapy in CLL patients
In this chapter, the hosts discuss the FLAIR trial, a large UK multi-center adaptive trial in CLL. They talk about the comparison between FCR (chemo immunotherapy) and M.R.D.-guided duration of broungeb-plus-videclacks therapy in untreated CLL patients. They delve into the performance of M.R.D. in both peripheral blood and bone marrow, the relevance of M.R.D. in the CLL context, and the potential benefits of personalized therapy. They also discuss the implications of the study results and the future of M.R.D. testing in CLL treatment.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
